# Immune Monitoring Laboratory

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $72,482

## Abstract

PROJECT SUMMARY/ABSTRACT
The Immune Monitoring Laboratory Shared Resource (IML) serves as a central hub for basic, translational,
and clinical research, uniquely positioned to bridge the wet-bench laboratory and the clinic. The IML mission is
to characterize and understand anti-tumor immune responses, determine mechanisms by which immune escape
and evasion occur, and predict patient responses and immune related toxicity in cancer immunotherapy trials in
support of Perlmutter Cancer Center (PCC) members. To this end, IML centralizes a large portfolio of expert
immune monitoring assays, providing easy and affordable access to state-of-the-art services and instrumentation
and a collaborative and educational environment for PCC faculty, staff, and students. Directed by Sara Borghi,
PhD, an immunologist with extensive expertise in the mechanistic aspects of human immunology and cancer
immunotherapy, co-directed by Peter Lopez, PhD, who has has 45 years of experience in flow cytometry, and
staffed by 6 other expert scientists, IML has been reorganized to align with PCC member needs for state-of-the
art and cutting-edge immune monitoring in support of their project goals and future plans. We collaborate closely
with The Applied Bioinformatics Laboratory Shared Resource (ABL), Center for Biospecimen Research and
Development Shared Resource (CBRD), Genome Technology Center Shared Resource (GTC), Metabolomics
Laboratory Shared Resource (MBX) and Experimental Pathology Shared Resource (ExPath). IML is critical for
the research of the four Research Programs, as immune monitoring is central to much of modern cancer
research. Most importantly, IML aspires to be flexible in meeting the individual needs of PCC members and in
coordinating and integrating different areas of expertise; these needs are assessed regularly via surveys and
meetings with an Advisory Board. Since 2018, IML has been used by 106 PCC investigators across all
programs, resulting in 168 funded peer-reviewed grants and 161 peer-reviewed publications. IML achieves
its mission via three Specific Aims: 1) To provide a wide portfolio of state-of-the art and cutting-edge immune
monitoring services, including a broad array of cytometry technologies and multimodal single-cell analyses, and
to evaluate and implement emerging technologies in support of PCC research needs, 2) To provide assistance
and expert guidance from experimental design to data interpretation to PCC investigators - IML supports
translational cancer immunology, immunotherapy studies, and trial development, providing results that are
robust, accessible, and interpretable by researchers and clinicians; and 3) To educate and inform members of
the PCC community through hands-on training and development and dissemination of protocols and best
practices for cutting-edge immune monitoring technologies, with the goal of retaining and enhancing our
reputation as leaders in single cell technology.

## Key facts

- **NIH application ID:** 10769331
- **Project number:** 2P30CA016087-43
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Sara Borghi
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $72,482
- **Award type:** 2
- **Project period:** 1996-12-01 → 2029-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10769331

## Citation

> US National Institutes of Health, RePORTER application 10769331, Immune Monitoring Laboratory (2P30CA016087-43). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10769331. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*